Vitamin D3 for Life

Live Enlightened

Physiology

Infant Vitamin D Sources and Status: Study Summary

Previous related pageInfant Vitamin D Sources and Status: Full Evidence ReviewNext related pageInfant Vitamin D Sources and Status: Full Evidence Review
Study at a glance

What was studied?

Researchers compared vitamin D supplementation strategies in infants. Some infants were born at term, at the usual stage of pregnancy. Others were born early and received specialist care. One trial compared a supplement given to breastfeeding mothers with a supplement given directly to infants. Most studies measured 25-hydroxyvitamin D, a blood substance used to assess vitamin D status.

What did the studies find?

Higher infant doses generally raised the blood measurement. In term infants, this did not consistently produce an added bone benefit. A tested high-maternal-dose strategy produced similar infant blood status to direct infant supplementation among pairs who continued breastfeeding. An intermediate maternal-dose arm was stopped because of infant deficiency.

What does this mean?

A supplement can change a blood result without proving better health. Starting status, feeding circumstances and other nutritional sources matter. A supplement dose is not always the total amount received.

What are the limits?

Some trials were small or lost many participants during follow-up. The studies of infants born early were short. Milk vitamin D was not measured in the maternal-route trial. These studies do not establish one best intake or blood target for every infant. Research doses are not instructions for infant care.

Read the full article below ↓

Vitamin D studies in infants measure different things. Some ask whether a supplement changes a blood result. Others ask whether it improves health. This summary explains what six independent trial groups found about vitamin D sources and blood-level changes in infants born at term and infants born early. For the methods, comparisons and limitations, read Infant Vitamin D Sources and Status: Full Evidence Review.

What was the question?

The studies asked how vitamin D status changes with the supplement amount, the infant’s starting status, feeding circumstances and the person receiving the supplement. Most measured 25-hydroxyvitamin D, usually written as 25(OH)D. This is a substance the body produces when it processes vitamin D. It is used to assess vitamin D status. It is different from vitamin D3 in a supplement and from the active vitamin D hormone. These blood markers are explained in Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D, and their conversion in Vitamin D Activation.

A higher blood result does not, by itself, show that an infant has stronger bones or fewer illnesses. The amount assigned as a supplement may also differ from total intake when other feeds supply vitamin D. Research doses are descriptions of experiments, not instructions for an infant’s care. IU means international units.

For current UK guidance, see NHS Vitamins for children. Infants born early need advice from their neonatal team.

What happened in term infants?

In Montreal, Gallo and colleagues studied 132 healthy breastfed infants born at term, meaning at the usual stage of pregnancy. They compared four daily supplement amounts, from 400 to 1,600 IU. Blood-level responses differed, but higher amounts did not show an added growth or bone-mineral benefit. The highest-dose arm was stopped after high results from one laboratory method. Later measurements were lower, and further safety investigations were normal. This was not proof of toxic injury (Gallo et al., 2013).

The Finnish VIDI trial compared 400 with 1,200 IU daily from two weeks to two years. It included 975 infants in the analysis. Most already had sufficient vitamin D status at birth. The higher dose raised blood levels but did not add a detected bone benefit or reduce the overall rate of reported infections (Rosendahl et al., 2018).

A separate Montreal trial selected 98 infants with low vitamin D status at birth and assigned them by chance to two supplement groups. It compared 400 with 1,000 IU daily, starting at about one month. The higher amount raised blood levels without a demonstrated bone-mineral advantage. Another report from the same trial found modestly higher absolute lean mass with the higher dose at 12 months, but no matching improvement in the proportion of lean tissue, lean mass adjusted for length, or fat outcomes. Lean mass includes soft tissue other than fat, including muscle. This does not show stronger muscles or prevention of later obesity (Gharibeh et al., 2023; Razaghi et al., 2022).

Could a maternal supplement affect a breastfed infant’s status?

Hollis and colleagues compared supplementation given to the mother with supplementation given directly to the infant. Among pairs who continued breastfeeding, the tested high-maternal-dose strategy produced infant blood status similar to the direct-infant strategy. An intermediate maternal-dose arm was stopped because infants developed low vitamin D status. Many pairs stopped breastfeeding during follow-up, and milk vitamin D was not measured. The result does not establish that every maternal regimen can replace infant supplementation, or that the strategies have equal clinical benefits and safety (Hollis et al., 2015, corrected 2019).

What happened in preterm infants?

A 2025 trial in Chiang Mai compared supplemental doses of 400 and 800 IU in 38 infants born early or with very low birthweight. The higher-dose group had higher vitamin D status at six weeks of age, after about four to five weeks of treatment. Calcium, phosphate and alkaline phosphatase, a protein that helps chemical reactions, did not show an added benefit. The study did not test improved bone scans or fewer fractures. Other nutrition and mineral care contributed to the infants’ exposure (Rueang-Amnat et al., 2025).

A smaller Nebraska trial also found higher vitamin D status at four weeks with 800 rather than 400 IU. Its later numbers and bone reporting contain disagreements, so those disputed results are not used here (Anderson-Berry et al., 2017).

What does this mean?

Starting status, feeding route, other nutritional sources and prematurity all affect the interpretation. The trials show that different strategies can change infant blood levels. They do not establish one best intake or blood target for every infant. This distinction is explained in Why a Vitamin D Deficiency Threshold Is Not the Same as a Functional Target. Findings from a neonatal unit should not be transferred directly to a healthy term infant at home.

This is a summary of selected assessed studies, not a feeding guideline. The detailed review explains the sources, missing information and differences between trials. The separate outcomes review examines why a changed blood level and a health benefit need different evidence.

Sources

These are the same assessed sources used by the detailed review. Companion papers from one trial do not count as separate experiments. Unavailable supplementary details from the maternal-route and lean-mass papers are not used to make precise safety, subgroup or equivalence claims.

Maternal Versus Infant Vitamin D Supplementation During Lactation: A Randomized Controlled Trial. Correction. Pediatrics. 2019;144:e20191063. Figure 2B/C labels corrected; not a separate trial.

Correction of neonatal vitamin D status using 1000 IU vitamin D/d increased lean body mass by 12 months of age compared with 400 IU/d: a randomized controlled trial. Razaghi M et al. American Journal of Clinical Nutrition. 2022;115:1612 to 1625. Same trial as Gharibeh; the title refers to correcting status, not an erratum.

Randomized trial of two doses of vitamin D3 in preterm infants <32 weeks: Dose impact on achieving desired serum 25(OH)D3 in a NICU population. Anderson-Berry A et al. PLoS ONE. 2017;12:e0185950. DOI: 10.1371/journal.pone.0185950.

Related reading

Library

Diverse Effects of Combinations of Maternal-Neonatal VDR Polymorphisms and 25-Hydroxyvitamin D Concentrations on Neonatal Birth Anthropometry: Functional Phenocopy Variability Dependence, Highlights the Need for Targeted Maternal 25-Hydroxyvitamin D Cut-Offs during Pregnancy

The aim of this study was to evaluate the combined effect of maternal and neonatal VDR polymorphisms (ApaI, TaqI, BsmI, FokI, Tru9I) and different maternal and neonatal 25(OH)D cut-offs on neonatal birth anthropometry.

Original paper ↗Read more →

Original sources

Source

Vitamins for children

For current UK guidance, see NHS Vitamins for children.

Publication details

For current UK guidance, see NHS Vitamins for children. Infants born early need advice from their neonatal team.

Read more →
Source

Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial

Published in Gharibeh N et al. JAMA Pediatrics (2023).

Publication details

Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Gharibeh N et al. JAMA Pediatrics. 2023;177:353 to 362. DOI: 10.1001/jamapediatrics.2022.5837.

Read more →
Source

Correction of neonatal vitamin D status using 1000 IU vitamin D/d increased lean body mass by 12 months of age compared with 400 IU/d: a randomized controlled trial

Published in Razaghi M et al. American Journal of Clinical Nutrition (2022).

Publication details

Correction of neonatal vitamin D status using 1000 IU vitamin D/d increased lean body mass by 12 months of age compared with 400 IU/d: a randomized controlled trial. Razaghi M et al. American Journal of Clinical Nutrition. 2022;115:1612 to 1625. Same trial as Gharibeh; the title refers to correcting status, not an erratum.

Read more →